文献速递冠心病

无传统心血管危险因素ACS患者PCI术后替格瑞洛与氯吡格雷的比较

[Efficacy and safety of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with acute coronary syndrome without standard modifiable cardiovascular risk factors].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2026-01-01

结果显示两组主要不良心血管事件发生率差异无统计学意义,但替格瑞洛组出血学术研究联合会2、3、5型出血发生率显著高于氯吡格雷组。结论提示该人群使用氯吡格雷可能是更合理的P2Y12受体抑制剂选择。

要点

  • 无传统心血管危险因素ACS患者PCI术后,替格瑞洛与氯吡格雷12个月缺血事件无显著差异。
  • 替格瑞洛组出血学术研究联合会2、3、5型出血发生率显著高于氯吡格雷组。
  • 该人群选择氯吡格雷可能在保证缺血获益的同时降低出血风险。

核心结论

  • 在无传统心血管危险因素的ACS患者中,PCI术后使用替格瑞洛相比氯吡格雷未降低缺血事件,但显著增加出血风险。
  • 氯吡格雷可能是该人群更合理的P2Y12受体抑制剂选择。

研究设计与样本

  • 基于单中心前瞻性PCI注册数据库的回顾性队列研究。
  • 无传统心血管危险因素定义为入院时无高血压、糖尿病、高脂血症或活动性吸烟。

主要发现

  • 替格瑞洛组急性心肌梗死比例较高,年龄较小,男性比例较高,估算肾小球滤过率和血红蛋白水平较高。
  • 12个月主要不良心血管事件发生率在替格瑞洛组与氯吡格雷组间差异无统计学意义。
  • 替格瑞洛组出血学术研究联合会2、3、5型出血发生率高于氯吡格雷组。

临床怎么用

  • 对于无传统心血管危险因素的ACS患者,PCI术后抗血小板治疗应个体化评估缺血与出血风险。
  • 该人群使用替格瑞洛未带来额外缺血获益且显著增加出血,氯吡格雷可能是更合适的P2Y12受体抑制剂。

局限性

  • 本研究为回顾性队列研究,存在残余混杂可能。
  • 研究基于单中心注册数据,结果外推至其他中心或人群需谨慎。
  • 两组基线特征存在差异,尽管采用多因素Cox回归校正,仍可能有未知混杂因素影响结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of ticagrelor versus clopidogrel in real-world patients with acute coronary syndrome (ACS) without standard modifiable cardiovascular risk factors (SMuRF-less) following percutaneous coronary intervention (PCI). Methods: This retrospective cohort study was based on a single-center, prospective PCI registry. SMuRF-less ACS patients (defined as the concurrent absence of hypertension, diabetes mellitus, hyperlipidemia, and current smoking at admission) who underwent PCI at the General Hospital of Northern Theater Command between March 2016 and March 2023 were consecutively enrolled. Patients were categorized into clopidogrel and ticagrelor groups based on the P2Y12 receptor inhibitor prescribed at discharge. The primary efficacy endpoint was major adverse cardiovascular events at 12 months, defined as a composite of cardiac death, myocardial infarction, or ischemic stroke. The primary safety endpoint was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding. Multivariable Cox proportional hazards regression models were used to compare outcomes between the two groups. Results: A total of 3 323 SMuRF-less ACS patients were included (age (61.8±10.6) years; 1 120 (33.7%) female), comprising 2 694 (81.1%) in the clopidogrel group and 629(18.9%) in the ticagrelor group. Compared with the clopidogrel group, the ticagrelor group had a higher proportion of acute myocardial infarction, younger age, a higher proportion of males, and higher estimated glomerular filtration rate and hemoglobin levels (all P<0.05). During the 12-month follow-up, the incidence of the primary efficacy endpoint, major adverse cardiovascular events, did not differ significantly between the ticagrelor and clopidogrel groups (1.4% (9/629) vs. 2.0% (55/2 694), HR=0.90, 95%CI: 0.43-1.87, P=0.778). However, the ticagrelor group had a significantly higher incidence of the primary safety endpoint, Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, compared with the clopidogrel group (9.2% (58/629) vs. 5.9% (160/2 694), HR=1.79, 95%CI: 1.30-2.47, P<0.001). Conclusions: Among SMuRF-less ACS patients undergoing PCI, ticagrelor did not reduce ischemic events compared with clopidogrel, but was associated with a significantly higher bleeding risk. Clopidogrel may represent a more appropriate P2Y₁₂ receptor inhibitor for this population. 目的: 评估真实世界中无传统心血管危险因素的急性冠脉综合征(ACS)患者在经皮冠状动脉介入治疗(PCI)术后使用替格瑞洛和氯吡格雷的有效性和安全性。 方法: 本研究是一项基于单中心前瞻性PCI注册数据库的回顾性队列研究,连续纳入2016年3月至2023年3月在解放军北部战区总医院住院并接受PCI治疗的无传统心血管危险因素(入院时无高血压、糖尿病、高脂血症或活动性吸烟)的ACS患者,根据患者出院使用的P2Y12受体抑制剂种类分为氯吡格雷组和替格瑞洛组。PCI术后随访12个月,主要有效性终点为主要不良心血管事件,定义为心原性死亡、心肌梗死或缺血性卒中的复合终点;主要安全性终点为出血学术研究联合会2、3、5型出血事件。采用多因素Cox回归模型比较两组终点事件的差异。 结果: 共纳入3 323例无传统心血管危险因素的ACS患者,年龄(61.8±10.6)岁,女性1 120例(33.7%),其中氯吡格雷组2 694例(81.1%),替格瑞洛组629例(18.9%)。与氯吡格雷组相比,替格瑞洛组中急性心肌梗死患者比例较高,年龄较小,女性比例较低,而估算的肾小球滤过率及血红蛋白水平较高(P均<0.05)。随访12个月期间,替格瑞洛组与氯吡格雷组的主要有效性终点即主要不良心血管事件发生率差异无统计学意义[1.4%(9/629)比2.0%(55/2 694),HR=0.90(95%CI:0.43~1.87),P=0.778]。替格瑞洛组主要安全性终点即出血学术研究联合会2、3、5型出血发生率高于氯吡格雷组[9.2%(58/629)比5.9%(160/2 694),HR=1.79(95%CI:1.30~2.47),P<0.001]。 结论: 对于无传统心血管危险因素的ACS患者,与氯吡格雷相比,替格瑞洛未能降低缺血风险,且显著增加出血风险,氯吡格雷可能是该人群更合理的P2Y12受体抑制剂选择。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Na, Qiu, Wang, et al. [Efficacy and safety of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with acute coronary syndrome without standard modifiable cardiovascular risk factors]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 42324102. doi:10.3760/cma.j.cn112148-20260204-00080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。